KYMERA THERAPEUTICS, INC. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
KYMERA THERAPEUTICS, INC. (KYMR) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 10.51 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-05
- KYMERA THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 10.89M shares, a 10.18% decline year-over-year.
- KYMERA THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 12.13M shares, a 14.38% increase year-over-year.
- KYMERA THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 10.60M shares, a 21.24% increase year-over-year.
- KYMERA THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-03-31 was 8.74M shares, a 20.76% increase year-over-year.
- KYMERA THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 10.35M shares, a 1.49% increase from fiscal 2024.
- KYMERA THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 10.20M shares, a 17.13% increase from fiscal 2023.
- KYMERA THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 8.71M shares, a 23.68% increase from fiscal 2022.
- KYMERA THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 7.04M shares, a 12.14% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|---|---|---|
| 2026-06-30 | 10.51M shares 10-Q · filed 2026-08-05 | |||
| 2026-03-31 | 10.89M shares 10-Q · filed 2026-04-30 | |||
| 2025-12-31 | 10.35M shares 10-K · filed 2026-02-26 | |||
| 2025-09-30 | 11.91M shares 10-Q · filed 2025-11-04 | |||
| 2025-06-30 | 12.23M shares 10-Q · filed 2026-08-05 | |||
| 2025-03-31 | 12.13M shares 10-Q · filed 2026-04-30 | |||
| 2024-12-31 | 10.20M shares 10-K · filed 2026-02-26 | |||
| 2024-09-30 | 10.41M shares 10-Q · filed 2025-11-04 | |||
| 2024-06-30 | 10.54M shares 10-Q · filed 2025-08-11 | |||
| 2024-03-31 | 10.60M shares 10-Q · filed 2025-05-09 | |||
| 2023-12-31 | 8.71M shares 10-K · filed 2026-02-26 | |||
| 2023-09-30 | 8.84M shares 10-Q · filed 2024-10-31 | |||
| 2023-06-30 | 8.84M shares 10-Q · filed 2024-08-07 | |||
| 2023-03-31 | 8.74M shares 10-Q · filed 2024-05-02 | |||
| 2022-12-31 | 7.04M shares 10-K · filed 2025-02-27 | |||
| 2022-09-30 | 7.29M shares 10-Q · filed 2023-11-02 | |||
| 2022-06-30 | 7.43M shares 10-Q · filed 2023-08-03 | |||
| 2022-03-31 | 7.24M shares 10-Q · filed 2023-05-04 | |||
| 2021-12-31 | 6.28M shares 10-K · filed 2024-02-22 | |||
| 2021-09-30 | 6.68M shares 10-Q · filed 2022-11-03 | |||
| 2021-06-30 | 6.89M shares 10-Q · filed 2022-08-09 | |||
| 2021-03-31 | 6.91M shares 10-Q · filed 2022-05-03 | |||
| 2020-12-31 | 1.69M shares 10-K · filed 2023-02-23 | |||
| 2020-09-30 | 5.79M shares 10-Q · filed 2021-11-10 | |||
| 2020-06-30 | 36.13M shares 10-Q · filed 2021-08-06 | |||
| 2020-03-31 | 35.00M shares 10-Q · filed 2021-05-06 | |||
| 2019-12-31 | 25.50M shares 10-K · filed 2022-02-24 | |||
| 2019-09-30 | 32.55M shares 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |